With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Join Drs. Garratt and Waksman as they discuss the recent information overload from drug-eluting stent trials and to what extent these data impact their clinical practice.
Despite data suggesting that only the culprit lesion should be treated in ACS patients, it's often hard to ignore significant blockages seen on angiography. Dr. Feres presents a case to Drs. Bhatt and King who discuss strategies to quantify risk and manage ACS patients with multivessel disease.
Drs Moses, Singh and DeGregorio present a series of challenging case studies of patients with complex cardiovascular lesions and discuss how new and evolving technologies will impact the management of these patients.
Recorded at the Dallas-Leipzig meeting 2009. Watch presentations by Drs. Dewey, Kappetein, Schuler, and Walther bookended by commentary from course directors, Drs. Mack and Mohr.
COMPARE, ENDEAVOR IV, SIRTAX-LATE, SPIRIT IV -- given the abundance of data comparing the various DES are there any patterns emerging? Dr. King leads a panel discussion with Drs. Cohen and Williams.
The percutaneous pulmonary valve (PPV) was the first transcatheter valve developed. Dr. Ziyad Hijazi discusses this work with PPV inventor, Dr. Philipp Bonhoeffer, including the European and US experience so far in patients with prior right ventricular outflow tract surgery.
SYNTAX and MAIN-COMPARE suggest a role for PCI in subsets of patients with left main disease; however, in current ACC/AHA guidelines this remains a class III indication. Dr. Turco chairs a roundtable with interventionalists Drs Kandzari and Park and surgeon Dr Sabik.
The PARTNER and PAVIS trials of transcatheter aortic valve implementation will include inoperable or very high-surgical-risk patients. In Europe, where the devices have been approved for a few years, the technology is being expanded to lesser-risk patients. Interventionalist Dr Jeffrey Popma discusses the selection of patients with surgeon Dr Mathew Williams.
Dr. Dean Kereiakes leads an international panel of experts, Drs. Meredith, Banning, and Hermiller, as they discuss fascinating developments in stent and polymer technology and design their "dream stent."
How do drug-eluting stents compare? Our panel of experts, Drs. Stone, Kereiakes, Serruys, and Windecker discuss the late-breaking trials at TCT 2009 of DES vs DES.
Since BARI, CABG has been the gold standard for patients with diabetes and multivessel disease. However, SYNTAX suggests an increasing role for PCI and BARI 2D highlights the importance of optimal medical therapy. Dr. Boden leads a multidisciplinary discussion with Drs. Holmes and Taggart.
With the recent approval of a third-generation thienopyridine, choice of agent can be added to the list of considerations in the management of ACS patients, as well as the appropriate timing and dosing of thienopyridine. Using some case vignettes, Dr. King leads a discussion with Drs. Bhatt and Steg on their clinical decision-making.
From SOLACI 2009 in Rio de Janeiro. Dr. Mahmud hears how Dr. Feres interprets the data on antiplatelet/antithrombin strategies for his practice in Brazil.
Transcatheter aortic valve implantation (TAVI) has been approved in Europe since 2007, whereas these devices are just entering large-scale research trials in the United States. Dr. Popma leads a panel discussion with European interventionalist Dr. Eberhard Grube and surgeon Dr. Neil Moat on their experiences with TAVI.
Recently published data suggest that prior polyvascular disease increases the risk for inhospital adverse events in patients with ACS. Join Drs. Deepak Bhatt, Jean-Pierre Bassand, and José R. Gonzalez-Juanatey for a discussion of the current data on identification and management of patients with polyvascular disease.
Given SYNTAX, is left main stenting ready for primetime? Do the NCDR data lay to rest DES safety concerns? Recorded at EuroPCR 2009, Dr. Popma discusses the current status and future roles of PCI and DES with Drs.Gershlick and Tamburino.
How do the results of the SYNTAX trial impact clinical practice now? Join Drs. Banning and Hill as they present a complex case taken directly from the SYNTAX trial and discuss how new data will impact their choice of treatment, and listen to an overview of the trial presented by Dr. William Wijns.
AF can lead to stroke, congestive heart failure, and other serious complications. Successful management should include reducing these risks. Join our expert panel, Drs. Peter Rothwell, Donald Easton, and Mark Alberts, as they discuss new data and strategies for improving outcomes in patients with AF.
Despite modern therapy, the rates of death, MI, bleeding, and readmission remain high in patients with ACS. Join Drs. Jeffery Popma, Héctor Bueno, Freek Verheugt, and Sunil. Rao for a review of the latest data on antiplatelet therapy for patients with ACS.
Variable rate contrast delivery systems have the potential to improve workflow and patient outcomes by providing a more precise flow of contrast. Watch Dr. Jeffrey Moses and his team as they demonstrate the use of the device in the cath lab in a patient with complex lesions.
Surgery? PCI? How do we choose the optimal therapy for any given patient? Join our panel of experts, Drs. Feldman, Cohen, Kereiakes, Leon, and Mohr as they discuss latest data on treating complex lesions.
When choosing between DES and BMS or among the various DES, how much weight should be given to 1-year data vs the totality of evidence? What is the duration of stent thrombosis risk? Dr. Leon leads a panel discussion to address these issues with Drs. Kandzari and Yeung.
Learn about the current status of less-invasive strategies to repair thoracic aneurysms as Dr. Mack leads a discussion with vascular surgeons, Drs. Kasirajan and Woo. Which cases are amenable to endovascular repair and which require open surgery?
Despite data suggesting that only the culprit lesion should be treated in ACS patients, it's often hard to ignore significant blockages seen on angiography. Dr. Feres presents a case to Drs. Bhatt and King who discuss strategies to quantify risk and manage ACS patients with multivessel disease.
COMPARE, ENDEAVOR IV, SIRTAX-LATE, SPIRIT IV -- given the abundance of data comparing the various DES are there any patterns emerging? Dr. King leads a panel discussion with Drs. Cohen and Williams.
Join Drs. Garratt and Waksman as they discuss the recent information overload from drug-eluting stent trials and to what extent these data impact their clinical practice.
Drs Moses, Singh and DeGregorio present a series of challenging case studies of patients with complex cardiovascular lesions and discuss how new and evolving technologies will impact the management of these patients.
Recorded at the Dallas-Leipzig meeting 2009. Watch presentations by Drs. Dewey, Kappetein, Schuler, and Walther bookended by commentary from course directors, Drs. Mack and Mohr.
The percutaneous pulmonary valve (PPV) was the first transcatheter valve developed. Dr. Ziyad Hijazi discusses this work with PPV inventor, Dr. Philipp Bonhoeffer, including the European and US experience so far in patients with prior right ventricular outflow tract surgery.
How do drug-eluting stents compare? Our panel of experts, Drs. Stone, Kereiakes, Serruys, and Windecker discuss the late-breaking trials at TCT 2009 of DES vs DES.